News &amp; Updates

Early pulmonary hypertension (PH) is highly prevalent among infants born preterm and appears to be related to the development of bronchopulmonary dysplasia (BPD), a recent study has found.

Product Highlight - VPRIV

Velaglucerase alfa, Powder for solution for infusion

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022 by

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Hyperuricaemia modulates HDL-C-induced cardiovascular mortality in women

Women with very high levels of high-density lipoprotein cholesterol (HDL-C) are at heightened risk of cardiovascular mortality, with the association following a J-shaped pattern, as reported in a study. Of note, the risk of cardiovascular mortality increases with concomitant hyperuricaemia.

Low-dose polypill: Another step forward in hypertension management?

A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.

12 Dec 2022

Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib

The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.

12 Dec 2022

Antipsychotic use lowers work disability risk

Use of antipsychotics, particularly long-acting injectables, results in nearly 30‒50-percent reduced risk of work disability among individuals with first-episode nonaffective psychosis compared with nonuse, a study has shown. This benefit persists beyond 5 years after first diagnosis.

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

First-line treatment with durvalumab plus gemcitabine and cisplatin (GC) leads to improved overall (OS) and progression-free survival (PFS) in advanced biliary tract cancer (BTC) across genomic variants, according to the results of the phase III study TOPAZ-1, presented at the ESMO Asia 2022.

Which factors prevent or enable the safe handling of antineoplastic drugs?

Several barriers and facilitators indicate the need to create work environments where safety is a priority for the handling of antineoplastic drugs, suggests a Canada study.

Resmetirom safe, effective in improving NASH fibrosis markers

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.